| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (NCT05032040) | Xencor, Inc. | 2022-07-21 |
| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T (NCT05468190) | Chongqing Precision Biotech Co., Ltd | 2022-07-17 |
| Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice (NCT06103916) | Maxima Medical Center | 2022-07-15 |
| Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (NCT05200260) | Shanghai Gynecologic Oncology Group | 2022-07-13 |
| Project CADENCE (CAncer Detected Early caN be CurEd) (NCT05633342) | MiRXES Pte Ltd | 2022-07-07 |
| Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer (NCT06775470) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-07-01 |
| Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer (NCT05113368) | Sarah K. Lynam MD | 2022-06-28 |
| Comprehensive Outcomes for After Cancer Health (NCT05349227) | Pack Health | 2022-06-23 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (NCT05256381) | SOTIO Biotech AG | 2022-06-21 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NCT05429970) | Memorial Sloan Kettering Cancer Center | 2022-06-17 |
| The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression (NCT06320418) | Ain Shams University | 2022-06-15 |
| A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (NCT05360680) | Cue Biopharma | 2022-06-14 |
| Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer (NCT05375526) | Maastricht University Medical Center | 2022-06-01 |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05395052) | Fate Therapeutics | 2022-05-31 |
| Erdafitinib in Metastatic Steroid-cell Ovarian Cancer (NCT06328491) | University Health Network, Toronto | 2022-05-30 |
| OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer (NCT04941378) | Abramson Cancer Center at Penn Medicine | 2022-05-28 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451) | M.D. Anderson Cancer Center | 2022-05-10 |
| Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin (NCT05514028) | ZIWIG | 2022-05-04 |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (NCT05366881) | Adela, Inc | 2022-05-03 |
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (NCT04918186) | Canadian Cancer Trials Group | 2022-05-03 |
| Transcriptional Map of Ovarian Cancer at the Single Cell Level (NCT05030805) | University Hospital, Strasbourg, France | 2022-05-01 |
| Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (NCT05316129) | H. Lee Moffitt Cancer Center and Research Institute | 2022-04-28 |
| Michigan Genetic Hereditary Testing (MiGHT) (NCT05162846) | University of Michigan Rogel Cancer Center | 2022-04-21 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (NCT05363605) | Fusion Pharmaceuticals Inc. | 2022-04-20 |
| Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies (NCT05342506) | Peking Union Medical College Hospital | 2022-04-18 |
| Chemotherapy Supported by Autologous Hematopoietic Stem Cells (NCT05401162) | Chongqing University Cancer Hospital | 2022-04-15 |
| The DIALOGUE Study: Swiss-Korean Billateral Collaboration (NCT04214210) | University of Basel | 2022-04-15 |
| Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (NCT05372692) | Weijia Fang, MD | 2022-04-12 |
| The Culture of Ovarian Cancer Organoids and Drug Screening (NCT04768270) | Chongqing University Cancer Hospital | 2022-04-12 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
| A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer (NCT05258747) | Sandoz | 2022-04-07 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735) | Alaunos Therapeutics | 2022-04-04 |
| Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (NCT04997096) | Dana-Farber Cancer Institute | 2022-04-02 |
| A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer (NCT05824247) | The First Affiliated Hospital of Xiamen University | 2022-04-01 |
| The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study (NCT05265117) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-04-01 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Connecting Audio and Radio Sensing Systems to Improve Care at Home (NCT05344950) | UNC Lineberger Comprehensive Cancer Center | 2022-03-21 |
| Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment (NCT05274867) | The Christie NHS Foundation Trust | 2022-03-07 |
| New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence (NCT05410028) | Peking Union Medical College Hospital | 2022-03-03 |
| An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy (NCT05255861) | Xin Wu | 2022-03-01 |
| Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (NCT04575961) | North Eastern German Society of Gynaecological Oncology | 2022-02-22 |
| Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer (NCT05410015) | Peking Union Medical College Hospital | 2022-02-03 |
| Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NCT05183984) | ARCAGY/ GINECO GROUP | 2022-02-01 |
| Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution (NCT06222008) | Yandi Zhu | 2022-01-30 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (NCT05198804) | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 2022-01-27 |
| MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (NCT05255471) | National Cancer Institute, Naples | 2022-01-21 |
| Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) (NCT05123807) | M.D. Anderson Cancer Center | 2022-01-07 |
| Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies (NCT03762733) | National Cancer Institute (NCI) | 2022-01-04 |
| ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer (NCT05862740) | Azienda Ospedaliera di Padova | 2022-01-02 |
| Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids (NCT06317610) | Chongqing University Cancer Hospital | 2022-01-01 |
| Sexual Health Integration in Treatment of Gynecological Oncology (NCT06958068) | Medical University of Silesia | 2022-01-01 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer (NCT05187208) | Seoul National University Hospital | 2022-01-01 |
| IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection (NCT06977334) | Maharajgunj Medical Campus | 2022-01-01 |
| A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics (NCT05251883) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-01-01 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (NCT05420545) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (NCT05226507) | Nuvectis Pharma, Inc. | 2021-12-31 |
| A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer (NCT05170594) | The Second Affiliated Hospital of Shandong First Medical University | 2021-12-24 |
| Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701) | Astellas Pharma Global Development, Inc. | 2021-12-23 |
| Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (NCT04921527) | Chipscreen Biosciences, Ltd. | 2021-12-20 |
| Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (NCT04742075) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2021-12-15 |
| Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer (NCT05272462) | Loyola University | 2021-12-13 |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (NCT05116189) | Merck Sharp & Dohme LLC | 2021-12-13 |
| Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer (NCT05092763) | Northwestern University | 2021-12-10 |
| MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (NCT05233982) | National Cancer Institute, Naples | 2021-12-09 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (NCT05000294) | University of Florida | 2021-12-07 |
| Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients (NCT07039331) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-12-07 |
| Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (NCT05368207) | University Health Network, Toronto | 2021-12-06 |
| Patients Derived Organoids in Ovarian Cancer (NCT06085404) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-11-25 |
| Registry Platform Ovarian and Endometrial Cancer (NCT05129969) | iOMEDICO AG | 2021-11-25 |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer (NCT05103683) | TORL Biotherapeutics, LLC | 2021-11-17 |
| Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients (NCT04751435) | Memorial Sloan Kettering Cancer Center | 2021-11-16 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors (NCT05080946) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-02 |
| Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs (NCT05175326) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-11-01 |
| Asian Multicenter Prospective Study of ctDNA Sequencing (NCT05099978) | National Cancer Center, Japan | 2021-11-01 |
| First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (NCT05104515) | Oxford Vacmedix UK Ltd. | 2021-11-01 |
| Avera Cancer Sequencing and Analytics Protocol (ASAP) (NCT05142033) | Avera McKennan Hospital & University Health Center | 2021-11-01 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (NCT05537844) | Liz-Anne Lewsley | 2021-10-27 |
| Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer (NCT07684846) | University Medical Centre Ljubljana | 2021-10-23 |
| Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD (NCT05868889) | Grupo Español de Investigación en Cáncer de Ovario | 2021-10-21 |
| Exercise Preconditioning in Ovarian Cancer (NCT05029154) | University of Virginia | 2021-10-21 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients. (NCT05025878) | British Columbia Cancer Agency | 2021-10-20 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (NCT05041257) | AbbVie | 2021-10-19 |
| Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (NCT04847063) | National Cancer Institute (NCI) | 2021-10-19 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (NCT05123482) | AstraZeneca | 2021-10-18 |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma (NCT05043922) | Haihe Biopharma Co., Ltd. | 2021-10-11 |
| Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer (NCT05059782) | Xi'an Jiaotong University | 2021-10-10 |
| Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) (NCT04520074) | Fudan University | 2021-10-08 |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (NCT04931342) | Hoffmann-La Roche | 2021-10-07 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (NCT04853017) | Elicio Therapeutics | 2021-10-04 |
| Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer (NCT04891185) | Universitaire Ziekenhuizen KU Leuven | 2021-10-01 |
| Variance of HRD From Paired Ovarian Cancer (NCT05069818) | Xiaoxiang Chen | 2021-10-01 |
| EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer (NCT05715216) | M.D. Anderson Cancer Center | 2021-10-01 |